Nothing Special   »   [go: up one dir, main page]

MXPA06000401A - Derivados de naftileno como inhibidores de citocromo p450. - Google Patents

Derivados de naftileno como inhibidores de citocromo p450.

Info

Publication number
MXPA06000401A
MXPA06000401A MXPA06000401A MXPA06000401A MXPA06000401A MX PA06000401 A MXPA06000401 A MX PA06000401A MX PA06000401 A MXPA06000401 A MX PA06000401A MX PA06000401 A MXPA06000401 A MX PA06000401A MX PA06000401 A MXPA06000401 A MX PA06000401A
Authority
MX
Mexico
Prior art keywords
cytochrome
inhibitors
treatment
naphthylene
derivatives
Prior art date
Application number
MXPA06000401A
Other languages
English (en)
Spanish (es)
Inventor
Patricia Anne Beck
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of MXPA06000401A publication Critical patent/MXPA06000401A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
MXPA06000401A 2003-07-10 2004-07-12 Derivados de naftileno como inhibidores de citocromo p450. MXPA06000401A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10
PCT/US2004/022282 WO2005007631A1 (en) 2003-07-10 2004-07-12 Naphthylene derivatives as cytochrome p450 inhibitors

Publications (1)

Publication Number Publication Date
MXPA06000401A true MXPA06000401A (es) 2006-03-17

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06000401A MXPA06000401A (es) 2003-07-10 2004-07-12 Derivados de naftileno como inhibidores de citocromo p450.

Country Status (15)

Country Link
EP (1) EP1654236A1 (no)
JP (1) JP4832295B2 (no)
KR (1) KR20060052799A (no)
CN (1) CN1819996B (no)
AU (1) AU2004257257B2 (no)
BR (1) BRPI0412424A (no)
CA (1) CA2532078A1 (no)
IL (1) IL172812A0 (no)
IS (1) IS8223A (no)
MX (1) MXPA06000401A (no)
NO (1) NO20060114L (no)
RU (1) RU2363696C2 (no)
SG (1) SG144941A1 (no)
UA (1) UA87822C2 (no)
WO (1) WO2005007631A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058301A1 (en) * 2003-12-17 2005-06-30 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
US8513291B2 (en) 2010-06-01 2013-08-20 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
PT2638021T (pt) * 2010-11-13 2019-01-10 Innocrin Pharmaceuticals Inc 1-(6,7-bis(difluorometoxi)naftalen-2-il)-2-metil-1-(1h-1,2,3-triazol-4-il)propan-1-ol como inibidor de cyp17 para o tratamento de doenças dependentes de andrógeno, doenças tais como o cancro da próstata
EA201390876A1 (ru) * 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
CN102586187A (zh) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 一种中性粒细胞体外保存方法及培养基
US20160038490A1 (en) * 2012-07-18 2016-02-11 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
CN112961149A (zh) 2014-08-11 2021-06-15 安吉恩生物医药公司 细胞色素p450抑制剂及其用途
CN104523967B (zh) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 一种柏艾胶囊作为cyp酶抑制剂的应用
JP2018501279A (ja) 2014-12-31 2018-01-18 アンギオン バイオメディカ コーポレイション 疾患を治療するための方法及び薬剤
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
TW201837036A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物(一)
EP3568395A1 (de) 2017-01-10 2019-11-20 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (no) * 1960-05-04
NL131915C (no) * 1966-07-27
DE3508903A1 (de) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylmethylnaphtylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3628545A1 (de) * 1985-09-23 1987-04-23 Hoechst Ag Arylmethylazole und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
WO1994008973A1 (en) * 1992-10-21 1994-04-28 Sankyo Company, Limited Azole compound
DE69924717T2 (de) * 1998-04-23 2006-03-09 Takeda Pharmaceutical Co. Ltd. Naphthalene derivate ,ihre herstellung und verwendung
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 1−置換−1−(1h−イミダゾール−4−イル)メタノール類
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion

Also Published As

Publication number Publication date
AU2004257257A1 (en) 2005-01-27
WO2005007631A1 (en) 2005-01-27
IL172812A0 (en) 2006-06-11
NO20060114L (no) 2006-02-09
RU2363696C2 (ru) 2009-08-10
AU2004257257B2 (en) 2011-05-12
EP1654236A1 (en) 2006-05-10
RU2006103996A (ru) 2006-07-10
SG144941A1 (en) 2008-08-28
CA2532078A1 (en) 2005-01-27
UA87822C2 (ru) 2009-08-25
JP4832295B2 (ja) 2011-12-07
BRPI0412424A (pt) 2006-09-05
JP2007523866A (ja) 2007-08-23
KR20060052799A (ko) 2006-05-19
CN1819996A (zh) 2006-08-16
IS8223A (is) 2006-01-10
CN1819996B (zh) 2010-10-27

Similar Documents

Publication Publication Date Title
MXPA06000401A (es) Derivados de naftileno como inhibidores de citocromo p450.
AU2003297291A1 (en) Substituted arylcyclopropylacetamides as glucokinase activators
SG151286A1 (en) 5-substituted-2-phenylamino-benzamide as mek inhibitor
UA100501C2 (uk) Карбоксамідні сполуки і їх застосування як інгібіторів кальпаїнів
MY157949A (en) Thioxanthine derivatives as myeloperoxidase inhibitors
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
EP1505068A4 (en) PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND INHIBITOR OF NAD (P) H OXIDASE CONTAINING SAID DERIVATIVE
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
BR0316583A (pt) Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
MY145306A (en) Thieno [3,2-d] pyrimidine derivative useful as p13k inhibitor
HRP20040686B1 (hr) Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
PT1727551E (pt) Composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteína de fusão do rsv
HK1098372A1 (en) Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein
TNSN06338A1 (en) Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor
EP1775283A4 (en) 3-AMINOBENZAMIDE COMPOUND AND INHIBITORS OF THE ACTIVITY OF VANILLOID RECEPTOR 1 (VR1)
MXPA05011207A (es) Uso de derivados de 2,4-dihidro-[1,2,4]triazol-3-tiona como inhibidores de la enzima mieloperoxidasa (mpo).
MX2007006744A (es) Derivados de hidantoina utiles como inhibidores de metaloproteinasa.
MX2009011753A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
SI1601646T1 (sl) 2-substitirani vitamin d analogi in njihova terapevtska uporaba
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TW200407133A (en) Novel PPARα and PPARγ agonists
SE0302756D0 (sv) Novel Compounds
EP1127869A4 (en) NOVEL COMPOUNDS AND THEIR MEDICAL USE

Legal Events

Date Code Title Description
FG Grant or registration